Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943301765> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2943301765 endingPage "01" @default.
- W2943301765 startingPage "OT1" @default.
- W2943301765 abstract "Abstract Background: To date, the use of anti-androgens in the subset of triple negative breast cancers (TNBC) that express androgen receptor (AR) has shown modest response rates, indicating anti-androgen-resistance in the majority of these tumors. Based on data that Cyclin D kinase (CDK) inhibitors reverse resistance to anti-androgens in prostate cancer cell lines, we hypothesize that the use of CDK inhibition may enhance the activity of anti-androgens in AR-positive TNBC. Methods: Key eligibility include: patients with centrally confirmed AR-positive TNBC, defined as AR expression >0%; 0 to 1 line of prior therapy for metastatic disease; and measurable disease. Patients are treated with bicalutamide 150mg orally once daily plus ribociclib at one of 3 dose levels (see table). Table 1Dose levelBicalutamideRibociclib1150mg orally once daily (D1 to 28)400mg daily (D1 to 21)2150mg orally once daily (D1 to 28)400mg daily (D1 to 28)3150mg orally once daily (D1 to 28)600mg daily (D1 to 21) Results: AR expression was positive by trial criteria in 74% of screened patients. Three patients have been accrued at each dose level. Median age is 56 and 6 and 3 patients were treated in first and second-line settings, respectively. Median AR expression was 50% (range 5 to 75%). Toxicity data is available for 6-patients treated on dose levels 1 and 2. No dose-limiting toxicities were noted. As anticipated with ribociclib, the most common toxicity is neutropenia (1 patient grade 4 and 2 patients grade 3). Two patients experienced grade 3 hypertension and 1 experienced grade 3 lymphopenia. Grade 2 or lower toxicities included fatigue, nausea, hyperglycemia and mucositis. One patient experienced grade 1 QT interval prolongation. Conclusion: The combination of bicalutamide and ribociclib is tolerable without unexpected toxicities. Data on the 3-patients treated at dose level 3 and dose expansion will be included. Phase 2 dosing schedule will be decided based on phase 1 results. Citation Format: Sharifi M, Wisinski KB, Burkard ME, Tevaarwerk AJ, Tamkus D, Chan N, Truica C, Danciu O, Hoskins K, O'Regan RM. Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-02-01." @default.
- W2943301765 created "2019-05-09" @default.
- W2943301765 creator A5006752355 @default.
- W2943301765 creator A5011579642 @default.
- W2943301765 creator A5035708719 @default.
- W2943301765 creator A5037003848 @default.
- W2943301765 creator A5051615529 @default.
- W2943301765 creator A5052750238 @default.
- W2943301765 creator A5062976999 @default.
- W2943301765 creator A5075253555 @default.
- W2943301765 creator A5076344697 @default.
- W2943301765 creator A5081735541 @default.
- W2943301765 date "2019-02-15" @default.
- W2943301765 modified "2023-09-30" @default.
- W2943301765 title "Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer" @default.
- W2943301765 doi "https://doi.org/10.1158/1538-7445.sabcs18-ot1-02-01" @default.
- W2943301765 hasPublicationYear "2019" @default.
- W2943301765 type Work @default.
- W2943301765 sameAs 2943301765 @default.
- W2943301765 citedByCount "6" @default.
- W2943301765 countsByYear W29433017652020 @default.
- W2943301765 countsByYear W29433017652021 @default.
- W2943301765 countsByYear W29433017652023 @default.
- W2943301765 crossrefType "journal-article" @default.
- W2943301765 hasAuthorship W2943301765A5006752355 @default.
- W2943301765 hasAuthorship W2943301765A5011579642 @default.
- W2943301765 hasAuthorship W2943301765A5035708719 @default.
- W2943301765 hasAuthorship W2943301765A5037003848 @default.
- W2943301765 hasAuthorship W2943301765A5051615529 @default.
- W2943301765 hasAuthorship W2943301765A5052750238 @default.
- W2943301765 hasAuthorship W2943301765A5062976999 @default.
- W2943301765 hasAuthorship W2943301765A5075253555 @default.
- W2943301765 hasAuthorship W2943301765A5076344697 @default.
- W2943301765 hasAuthorship W2943301765A5081735541 @default.
- W2943301765 hasConcept C121608353 @default.
- W2943301765 hasConcept C126322002 @default.
- W2943301765 hasConcept C143998085 @default.
- W2943301765 hasConcept C2775930923 @default.
- W2943301765 hasConcept C2777063308 @default.
- W2943301765 hasConcept C2780110267 @default.
- W2943301765 hasConcept C2780192828 @default.
- W2943301765 hasConcept C2780962315 @default.
- W2943301765 hasConcept C29730261 @default.
- W2943301765 hasConcept C530470458 @default.
- W2943301765 hasConcept C61367390 @default.
- W2943301765 hasConcept C71924100 @default.
- W2943301765 hasConcept C90924648 @default.
- W2943301765 hasConceptScore W2943301765C121608353 @default.
- W2943301765 hasConceptScore W2943301765C126322002 @default.
- W2943301765 hasConceptScore W2943301765C143998085 @default.
- W2943301765 hasConceptScore W2943301765C2775930923 @default.
- W2943301765 hasConceptScore W2943301765C2777063308 @default.
- W2943301765 hasConceptScore W2943301765C2780110267 @default.
- W2943301765 hasConceptScore W2943301765C2780192828 @default.
- W2943301765 hasConceptScore W2943301765C2780962315 @default.
- W2943301765 hasConceptScore W2943301765C29730261 @default.
- W2943301765 hasConceptScore W2943301765C530470458 @default.
- W2943301765 hasConceptScore W2943301765C61367390 @default.
- W2943301765 hasConceptScore W2943301765C71924100 @default.
- W2943301765 hasConceptScore W2943301765C90924648 @default.
- W2943301765 hasIssue "4_Supplement" @default.
- W2943301765 hasLocation W29433017651 @default.
- W2943301765 hasOpenAccess W2943301765 @default.
- W2943301765 hasPrimaryLocation W29433017651 @default.
- W2943301765 hasRelatedWork W1500443874 @default.
- W2943301765 hasRelatedWork W2060740009 @default.
- W2943301765 hasRelatedWork W2317407876 @default.
- W2943301765 hasRelatedWork W2398079044 @default.
- W2943301765 hasRelatedWork W2400602137 @default.
- W2943301765 hasRelatedWork W2561387856 @default.
- W2943301765 hasRelatedWork W2905727460 @default.
- W2943301765 hasRelatedWork W2954455697 @default.
- W2943301765 hasRelatedWork W3006296916 @default.
- W2943301765 hasRelatedWork W3178587103 @default.
- W2943301765 hasVolume "79" @default.
- W2943301765 isParatext "false" @default.
- W2943301765 isRetracted "false" @default.
- W2943301765 magId "2943301765" @default.
- W2943301765 workType "article" @default.